Clinical Study On Rougan Sanjie Pills For PLC Patients With Qi-Stagnation And Blood-Stasis Syndrome After TACE Operation

Objective: To evaluate the clinical efficacy and safety of Rougan Sanjie Pills in the treatment of primary liver cancer(PLC)patients with Qi-Stagnation And Blood-Stasis Syndrome(QSBSS)after transcatheter arterial chemoembolization(TACE).Methods: A total of 78 PLC patients with QSBSS from January 2022 to October 2022 who were treated in the second District of Liver Disease,the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine were divided into the treatment group and the control group by random number table method,with 39 cases in each group.Two cases were shed during the study,and 76 cases were eventually included,with38 cases in each group.The control group was given TACE treatment +conventional Western medicine treatment,and the treatment group was given Rougan Sanjie Pill on the basis of the control group.The treatment course of the two groups was 12 weeks.The changes of liver function,liver cancer screening,vascular endothelial growth factor,TCM syndrome score,solid tumor efficacy,post embolization syndrome and quality of life score before and after treatment were observed and compared between the two groups.All the collected data were analyzed using SPSS 29.0 statistical software.Results:1.After the 4th week of treatment,in terms of liver function,alanine aminotransferase(ALT),aspartate aminotransferase(AST)and total bilirubin(TBIL)in 2 groups were decreased compared with before treatment(P<0.05),albumin(ALB)was increased in both groups compared with before treatment(P<0.05),the decrease rate of ALT,AST and TBIL in the treatment group was better than that in the control group,the difference was statistically significant(P<0.05),but the increase rate of ALB between the two groups was not significantly different,the difference was not statistically significant(P>0.05);In terms of the efficacy of solid tumor,there was no significant difference in tumor effective rate between the treatment group and the control group,which was not statistically significant(P>0.05).2.After the 12 th week of treatment,Liver function(ALT,AST,TBIL,ALB),liver cancer screening(AFP,AFP-L3,DCP),vascular endothelial growth factor(VEGF),solid tumor efficacy,TCM syndrome score,post-embolization syndrome(PES)symptom,and quality of life score were improved in 2 groups compared with before treatment(P<0.05),and there was no significant difference in improvement between groups except ALB(P>0.05),the improvement of other observation indexes in the treatment group was better than that in the control group,and the difference was statistically significant(P<0.05);Among them,the quality of life score,total efficacy of solid tumor and total efficacy of TCM syndromes in the treatment group were significantly higher than those in the control group,and the P values for comparison between groups were0.0011,0.002,0.003,the difference was statistically significant(P<0.05).Conclusion(s): After TACE treatment in PLC patients,Rougan Sanjie Pills can improve the early liver function of patients,reduce the level of tumor markers,reduce the formation of tumor neovascularization after surgery,improve the clinical symptoms of patients,improve the efficiency of tumor and middle medical treatment,reduce the occurrence of adverse reactions,improve the quality of life of patients,and improve their survival value,with high safety and no increase of adverse reactions.